Begins with 0 | NeoGenomics Laboratories

Dennis P. O’Malley, MD
Hematopathologist

Dr. O’Malley currently serves as a Hematopathologist at NeoGenomics and as an Adjunct Associated Professor at MD Anderson Cancer Center/University of Texas. Dr. O’Malley completed two hematopathology fellowships, one at Duke University and the second at Carolinas Medical Center. Dr. O’Malley has authored numerous articles, books and book chapters. He is the author of “Atlas of Splenic Pathology”, as well as a co-author of the AFIP Fascicle of Neoplastic Disorders of Lymph Node and Spleen, and was the first author on the AFIP Fascicle on Non-Neoplastic Disorders of Lymph Node and Spleen. Recent publications include chapters on lymphoma diagnosis in Dabbs’ Diagnostic Immunohistochemistry and several chapters in Knowles’ Hematopathology. Dr. O’Malley teaches at a broad range of venues. In addition to teaching at medical schools and residencies (such as MD Anderson, UCLA, USC) and state pathology societies (most recently Arizona), he is the director of a four-day ASCP course in hematopathology. He has been on several national committees and is currently a member of the CAP Immunohistochemistry Committee, and Cancer Biomarker Reporting Panel on both Myeloid disease and Lymphoma. Dr. O’Malley’s areas of diagnostic expertise include adult and pediatric bone marrow diseases, lymphomas, cutaneous hematologic disorders, splenic pathology, immunohistochemistry, flow cytometry and molecular diagnostics.

NeoLAB™ Prostate Kit

Kit Inside Dimensions:
4 5/8” L x 4” W x 4 5/8” H

Kit Components Included:

NeoLAB Prostate Kit box with foam insert
8” x 8” biohazard bag, 3 wall with absorbent
Refrigerant Pack, 3oz
2 x Vacutainer - 6 mL K2 EDTA PurpleTop Tube, Plastic
120 mL ClickSeal container, sterile
2 x Aqui-Pak, 4 bay absorbent pouch
3 x Patient ID and DOB 2” x 1” Direct Thermal Label
Parafilm 2” x 4” piece

Bladder FISH Kit

Kit Inside Dimensions:
4 5/8” L x 4” W x 4 5/8” H

Kit Components Included:

NeoGenomics Bladder FISH Kit box with foam insert
8” x 8” biohazard bag, 3 wall with absorbent
6.5 oz Collection Cup (180ml), Beaker style
Refrigerant Pack, 3 oz
Clickseal Container w/30mL Fill PreservCyt
Parafilm 2” x 4” piece

Hematopathology PLUS+ Kit

Kit Inside Dimensions:
7-1/4” L x 5-7/16” W x 2-1/2” H

Kit Components Included:

NeoGenomics Hematopathology Plus Box
10” x 10” Biohazard Bag w/ Pouch
2 x Vacutainer - 4 mL K2 EDTA Lavender Top Tube
2 x Vacutainer - 4 mL Sodium Heparin Green Top Tube
Vacutainer - 6 mL K2 EDTA Purple Top Tube, Plastic
Foam - Neo Bone Marrow Insert
2 x 20 mL vial with 10 mL fill of 10% NBF in 3” x 4” bags
2 x Slide Mailer, 5-slide
Label - Lot and Expiration
Refrigerant Pack, 3 oz
Aqui-Pak, 4 bay absorbent pouch
10 x Gold Seal Slides

We recommend the Hematopathology PLUS+ Kit if you are collecting bone marrow samples in an office setting. All components included.

NGS Non-Ewing Sarcoma Fusion Profile

The NGS Non-Ewing Sarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations unrelated to Ewing's sarcoma in the genes ALK, CAMTA1, CCNB3, CIC, EPC1, FOXO1, FUS, GLI1, HMGA2, JAZF1, MEAF6, MKL2, NCOA2, NTRK3, PDGFB, PLAG1, STAT6, TAF15, TCF12, TFE3, TFG, USP6, YWHAE, plus their fusion partners.

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.
Printable Test Details

Tumor Type	Translocation	Fusion Partners
Aneurysmal bone cyst	t(16;17)(q22;p13)	CDH11-USP6
	t(1;17)(p34.3;p13)	THRAP3-USP6
	t(3;17)(q21;p13)	CNBP-USP6
	t(9;17)(q22;p13)	OMD-USP6
	t(17;17)(q21;p13)	COL1A1-USP6
Angiofibroma	t(5;8)(p15;q13)	AHRR-NCOA2
Angiomatoid fibrous histiocytoma	t(12;22)(q13;q12)	EWSR1-ATF1
	t(2;22)(q33;q12)	EWSR1-CREB1
	t(12;16)(q13;p11)	FUS-ATF1
Alveolar rhabdomyosarcoma	t(2;13)(q35;q14)	PAX3-FKHR (PAX3-FOXO1)
Alveolar rhabdomyosarcoma	t(1;13)(p36;q14)	PAX7-FKHR (PAX7-FOXO1)
Alveolar soft-part sarcoma	der(17)t(X;17)(p11;q25)	ASPSCR1-TFE3
Chondroid lipoma	t(11;16)(q13;p13)	C11orf95-MKL2
Clear-cell sarcoma	t(12;22)(q13;q12)	EWSR1-ATF1
Clear-cell sarcoma	t(2;22)(q33;q12)	EWSR1-CREB1
Congenital/infantile fibrosarcoma	t(12;15)(p13;q25)	ETV6-NTRK3
Dermatofibrosarcoma protuberans/giant cell fibroblastoma	t(17;22)(q21;q13)	COLIA1-PDGFB
Dermatofibrosarcoma protuberans/giant cell fibroblastoma	t(17;22)(q21;q13)	COLIA1-PDGFB
Desmoplastic small round-cell tumor	t(11;22)(p13;q12)	EWSR1-WT1
Endometrial stromal sarcoma	t(7;17)(p15;q11)	JAZF1-JJAZ1(SUZ12)
	t(6;7)(p21;p15)	JAZF1-PHF1
	t(6;10)(p21;p11)	EPC-PHF1
	t(10;17)(q22;p13)	YWHAE-FAM22A/B
	t(1;6)(p32~34;p21)	MEAF6-PHF1
Epithelioid hemangioendothelioma	t(1;3)(p36;q25)	WWTR1-CAMTA1
Epithelioid hemangioendothelioma	t(X;11)(p11.2;q22.1)	TFE3-YAP1
Ewing sarcoma; Primitive neuroectodemal tumor (PNET)	t(11;22)(q24;q12)	EWSR1-FLI1
	t(21;22)(q22;q12)	EWSR1-ERG
	t(7;22)(p22;q12)	EWSR1-ETV1
	t(2;22)(q33;q12)	EWSR1-FEV
	t(17;22)(q12;q12)	EWSR1-E1AF
	inv(22)(q21;q12)	EWSR1-ZSG
	t(16;21)(p11;q22)	FUS-ERG
Ewing-like bone sarcoma	inv(X)(p11.4p11.22)	BCOR-CCNB3
Ewing-like bone sarcoma	t(20;22)(q13;q12)	EWSR1-NFATC2
Extraskeletal myxoid chondrosarcoma	t(9;22)(q22;q12)	EWSR1-NR4A3
	t(9;17)(q22;q11)	TAF15-NR4A3
	t(9;15)(q22;q21)	TCF12-NR4A3
	t(3;9)(q11;q22)	TFG-NR4A3
Giant cell fibroblastoma	t(17;22)(q21;q13)	COL1A1-PDGFB
Inflammatory myofibroblastic tumor	t(1;2)(q22;p23)	TPM3-ALK
	t(2;19)(p23;p13)	TPM4-ALK
	t(2;17)(p23;q23)	CLTC-ALK
	t(2;2)(p23;q13)	RANBP2-ALK
	t(2;11)(p23;p15)	CARS-ALK
	inv(2)(p23;q35)	ATIC-ALK
	t(2;4)(p23;q21)	SEC31A-ALK
Lipoblastoma	t(7;8)(p22;q13)	COL1A2-PLAG1
Lipoma	t(3;12)(q27-28;q14-q15)	HMGA2-LPP
Lipoma	t(3;12)(q27-28;q14-q15)	LPP-HMGA2
Low-grade fibromyxoid sarcoma	t(7;16)(q33;p11)	FUS-CREB3L2
Low-grade fibromyxoid sarcoma	t(11;16)(p11;p11)	FUS-CREB3L1
Meningeal hemangiopericytoma	inv(12)(q13q13)	NAB2-STAT6
Mesenchymal chondrosarcoma	t(8;8)(q13;q21)	HEY1-NCOA2
Myoepithelial tumor of soft tissue and bone	t(6;22)(p21;q12)	EWSR1-POU5F1
	t(19;22)(q13;q12)	EWSR1-ZNF444
	t(1;22)(q23;q12)	EWSR1-PBX1
	t with 16p11	FUS
Myxoid/round-cell liposarcoma	t(12;16)(q13;p11)	FUS-DDIT3
Myxoid/round-cell liposarcoma	t(12;22)(q13;q12)	EWSR1-DDIT3
Nodular fasciitis	t(17;22)(p13;q13)	MYH9-USP6
Pericytoma	t(7;12)(p22;q13)	ACTB-GLI1
Pulmonary myxoid sarcoma	t(2;22)(q34;q12)	EWSR1-CREB1
Sclerosing epithelioid fibrosarcoma	t(7;16)(p22;q24)	FUS-CREB3L2
Sclerosing epithelioid fibrosarcoma	t(11;16)(p13;p11.2)	FUS-CREB3L1
Solitary fibrous tumor	inv(12)(q13q13)	NAB2-STAT6
Spindle cell rhabdomyosarcoma	t(6;8)(p21;q13)	SRF-NCOA2
Spindle cell rhabdomyosarcoma	t(8;11)(q13;p15)	TEAD-NCOA2
Synovial sarcoma	t(X;18)(p11;q11)	SS18-SSX1
		SS18-SSX2
		SS18-SSX4
Undifferentiated small round blue cell tumor	t(4;19)(q35;q13)	CIC-DUX4
Undifferentiated small round blue cell tumor	t(10;19)(q26;q13)	CIC-DUX4

David L. Morgan, MD
Medical Director (Houston, Texas) and Hematopathologist

Prior to joining NeoGenomics in 2016, Dr. Morgan was the Medical Director of Flow Cytometry at Pathologists Bio-Medical/medfusion Laboratories in Texas. Formerly, Dr. Morgan served as Medical Director of Hematopathology at AmeriPath North Texas from 2005 to 2010. From 1992 to 2005, Dr. Morgan was a faculty member at Texas Tech University Health Sciences Center, and achieved the rank of tenured Professor of Anatomic and Clinical Pathology. He was also a recipient of the Alpha Omega Alpha Excellence in Teaching Award, and held positions as Director of Hematopathology and Flow Cytometry, Medical Director of the Cytogenetics and Molecular Diagnostics laboratories, and as Coordinator of the Pathology Residency Program. He obtained his medical degree from the University of Texas Southwestern Medical School in 1982. His residency in Anatomic and Clinical Pathology was at Presbyterian/St. Luke's Medical Center in Denver, Colorado. He then served as a staff pathologist at Swedish Medical Center in Englewood, Colorado. Dr. Morgan is a Fellow of the College of American Pathologists and the American Society for Clinical Pathology. test

General Specimen Transport Kit (large and small)

Large Kit Inside Dimensions:
7-1/4” L x 5-7/16” W x 2-1/2” H

Small Kit Inside Dimensions:
4-7/8” L x 4-1/4” W x 2-3/8” H

Includes box with foam insert. Kit Components must be ordered separately.

Available Kit Components:

13” x 18” biohazard bag (50/pack)
*6” x 9” biohazard bag, 3 walls with absorbent (50 pack with absorbent)
*4” x 6” plain ziplock bag (100 pack)
*Refrigerant Pack, 3oz (approximately 48/box)
4 mL sodium heparin green-top tube (10 pack)
4 mL K2-EDTA lavender top tube (10 pack)
*6 mL sodium heparin green-top tube (25 pack)
*6 mL K2-EDTA lavender top tube (25 pack)
5-slide slide mailer with 5 slides (10 pack)
*5-slide slide mailer, empty (10 pack)
40 mL vial with 20 mL fill of 10% NBF (12 pack)
40 mL vial with 10 mL fill of 10% NBF (24 histopack)
120 mL ClickSeal container, sterile
PreservCyt vials, 20 mL fill in 50 mL tube (10 pack)

*Commonly ordered with the General Specimen Transport Kit.

We recommend the General Specimen Transportation Kit and ordering individual components if you previously used: Neo Heme Basic Kit (small blue kit); HemePlus Kit (small red kit), Neo Solid Tumor Kit (small green kit), Neo FlexKIT (small/large purple kit), NeoSITE BE Kit (gray kit), Clarient IHC Kit (orange kit), Clarient Flow/Cyto Molecular Fresh Kit (blue kit); BE Esophagus FISH Kit.

Forrest J. Holmes Blocker, PhD
Director, Scientific Affairs

Dr. Blocker joined NeoGenomics after consulting for the pharmaceutical and biotechnology industries, specializing in the mechanism of cancer therapeutics, and serving on the faculty of the University of Texas and the University of New Mexico. She attended graduate school at the University of California at San Francisco and did a postdoctoral fellowship at The Scripps Research Institute in La Jolla. Her research has focused on the relationship between structure and function of macromolecules using physical techniques such as nuclear magnetic resonance and computation techniques such as homology modeling.

Hong Drum, MD
Hematopathologist, Pharma Services

Dr. Drum joined NeoGenomics as a Hematopathologist in 2017. Prior to joining NeoGenomics, Dr. Drum served as a Senior Hematopathologist at Genoptix Medical Laboratory for more than nine years. She completed her Anatomic Pathology / Clinical Pathology residency at Baptist Health System in Birmingham, AL and Hematopathology fellowship at New York University Medical Center. Dr. Drum is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. In addition to excellent diagnostic skills in Hematopathology, she has a strong interest in clinical research; she has published multiple papers, presented her research in national and international conferences, and served as a keynote speaker at one international conference. Dr. Drum has received multiple academic awards, including the Joseph J. Kleiner Memorial Award from American Society for Clinical Laboratory Science in 2010 for a research project/publication.

Maya Thangavelu, PhD
Director of Cytogenetics and Technical Director of FISH

Dr. McGill serves as the Director of Cytogenetics at NeoGenomics Laboratories at Fort Myers, Florida.

Dr. Maya Thangavelu is Director of Cytogenetics and Technical Director of FISH in Aliso Viejo, CA. She has extensive experience in academic and commercial laboratory settings, working with both constitutional and acquired cancer-related abnormalities. Dr. Thangavelu obtained her Ph.D. in Cytogenetics from Memorial University and her master’s degree in Genetic Counseling from Sarah Lawrence College. Following her postdoctoral fellowship at the University of Chicago, she held directorship of the Cytogenetics Laboratory and a faculty position at Northwestern University. Dr. Thangavelu is certified by the American Board of Medical Genetics in Clinical Cytogenetics, and is a fellow of the American College of Medical Genetics. She holds Cytogenetic Director licenses in California, Florida, and New York. Dr. Thangavelu is an approved CAP inspector.

Guoxian Sun, MD, DABMG, FACMG
Director of Cytogenetics

Dr. McGill serves as the Director of Cytogenetics at NeoGenomics Laboratories at Fort Myers, Florida.

Dr. Sun has held positions at Integrated Oncology Laboratories, Genzyme Genetics, and Impath. He served as a cytogenetics lab director for 12 years. Prior to that, he was an associate director of cytogenetics at Quest Diagnostics, San Juan Capistrano, CA. Dr. Sun earned his medical degree with a WHO fellowship in Hematology/Oncology at UCLA in 1987. He completed his genetics training from Alfigen - The Genetics Institute in Pasadena, CA. Dr. Sun is board certified in clinical cytogenetics. His main interest is cancer genetics, particularly in cytogenetic and genomic alterations of hematopoietic neoplasms. Dr. Sun has published over 40 scientific articles and abstracts.

John R. McGill, PhD, FACMGG
Director of Cytogenetics (Fort Myers, Florida)

Dr. McGill serves as the Director of Cytogenetics at NeoGenomics Laboratories at Fort Myers, Florida.

Dr. McGill has extensive experience in cancer genetics as an NIH-funded scientist, academician and practitioner of cancer cytogenetics and FISH. Prior to his career in diagnostic laboratories, he was Chief, Division of Molecular Genetics at the Cancer Therapy & Research Center in San Antonio, Texas where he also held an academic appointment as Associate Professor, in the Department of Cellular & Structural Biology at The University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Dr. McGill received his Ph.D. in Biomedical Sciences from The University of Texas Health Science Center at San Antonio, in San Antonio, Texas. He completed fellowships in the molecular biology of aging at the University of Arkansas for Medical Sciences in Little Rock, Arkansas and in medical genetics at The University of Texas Health Science Center at San Antonio, San Antonio, Texas. He is a founding fellow of the American College of Medical Genetics and is board certified in Clinical Cytogenetics by the American Board of Medical Genetics and Genomics. Dr. McGill holds Directors Licenses for the States of Florida, California, and New York.

Michele Hibbard Kempik, PhD, FACMG
Director of Genetics

Dr. Hibbard was the Director of Genetics at Clarient Diagnostic Services, Inc. for eight years prior to the NeoGenomics acquisition. Previously, she spent six years as Director of Genetics at Irvine-based U.S. Labs and a year at Impath labs in New York. She has been responsible for the launch and direction of the operations of the cytogenetics programs at each of these laboratories and the technical operations of the cytogenetic, FISH, and molecular genetic laboratories. Dr. Hibbard completed her clinical genetics training at Harvard Medical School. She completed her post-doctoral research in the Department of Pathology at Brigham and Women’s Hospital and her thesis research in the Department of Microbiology and Molecular Genetics at the University of California, Irvine. She is board certified by the American Board of Medical Genetics in Clinical Molecular Genetics and Clinical Cytogenetics, and holds California licenses as a Clinical Molecular Genetic Molecular Biologist and Clinical Cytogeneticist. She is a fellow in the American College of Medical Genetics and also holds her New York COQ in Cytogenetics, Oncology, and Molecular Tumor Markers.

Bob Gasparini, MS, CLSp(CG), CLDir
Consultant

Mr. Gasparini currently serves as a Consultant at NeoGenomics. Previously, he served as Chief Science Officer and on the Board of Directors. He also held the position of President from January 2005 through May 2011. Prior to joining NeoGenomics, Mr. Gasparini was Director of the Genetics Division for US Labs, and prior to that was the Molecular Marketing Manager for Ventana Medical Systems. Prior to Ventana, Mr. Gasparini was the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center, an affiliate of Mass General Hospital. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University. Mr. Gasparini is a licensed Clinical Laboratory Director and an accomplished author in the field of Cytogenetics and Fluorescence In-Situ Hybridization (FISH) testing. He received his BS in Biological Sciences from the University of Connecticut and his Master of Health Science from Quinnipiac University in Laboratory Administration.

Vincent Funari, PhD (CGMBS)
Technical Director of Molecular and Director of Clinical Bioinformatics

Dr. Funari's background is in medical genomics and genetics. He is formally trained in bioinformatics and genetics and licensed as a clinical molecular biology and genetics scientist. He comes to us as a previous Director of Genomics Core and Associate professor at UCLA Medical Center with over 45 peer reviewed co-authored publications in genomics such as Nature Immunology, JAMA, Science, Nature Genetics, AJHG, Genomics, etc. As faculty, he trained 4 medical genetics and 2 pathology fellows, in addition to teaching graduate student classes at Cedars-Sinai on genomic profiling. His primary interests are bioinformatics and genomic approaches to precision medicine.

After undergraduate research at University of California, Los Angeles, he completed his doctorate in a clinical genetics lab developing novel algorithms to diagnose human metabolic disease using high throughput genomic technologies. Afterward he completed a post-doctorate at Stanford University in Department of Surgery in the Pat Brown and David Botstein group characterizing the first molecular profiles of Breast Cancer. The next 10+ years were as faculty at the Medical Genetics Institute at Cedars-Sinai Medical Center, Department of Pathology, and Department of Pediatrics working closely with Dr. David Rimoin and Stan Nelson to implement precision medicine in the clinic.

Currently, he is the Technical Director of the molecular lab leading our clinical bioinformatics, working with R&D, and IT as well as Sales and Marketing to further develop and promote our molecular and genetic tests offerings.

NGS Rhabdomyosarcoma Fusion Profile

The NGS Rhabdomyosarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations related to rhabdomyosarcoma in the genes FOXO1, NCOA2, TFE3, plus their fusion partners.

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.

Printable Test Details

Tumor Type	Translocation	Fusion Partners
Alveolar rhabdomyosarcoma	t(2;13)(q35;q14)	PAX3-FKHR (PAX3-FOXO1)
Alveolar rhabdomyosarcoma	t(1;13)(p36;q14)	PAX7-FKHR (PAX7-FOXO1)
Alveolar soft-part sarcoma	der(17)t(X;17)(p11;q25)	ASPSCR1-TFE3
Spindle cell rhabdomyosarcoma	t(6;8)(p21;q13)	SRF-NCOA2
Spindle cell rhabdomyosarcoma	t(8;11)(q13;p15)	TEAD-NCOA2

NeoTYPE^® Liposarcoma Fusion Profile

The NeoTYPE Liposarcoma Fusion Profile combines next-generation sequencing to detect translocations in the genes EWSR1, FUS, HMGA2, PLAG1, plus their fusion partners. Additionally, FISH testing for MDM2 to detect amplifications relevant in liposarcoma is also performed.

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.

Printable Test Details

Tumor Type	Translocation	Fusion Partners
Lipoblastoma	t(7;8)(p22;q13)	COL1A2-PLAG1
Lipoma	t(3;12)(q27-28;q14-q15)	HMGA2-LPP
Lipoma	t(3;12)(q27-28;q14-q15)	LPP-HMGA2
Myxoid/round-cell liposarcoma	t(12;22)(q13;q12)	EWSR1-DDIT3

NGS Comprehensive Sarcoma Fusion Profile

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.

Printable Test Details

Dermatofibrosarcoma protuberans/giant cell fibroblastoma	t(17;22)(q21;q13)	COLIA1-PDGFB
Tumor Type	Translocation	Fusion Partners
Aneurysmal bone cyst	t(16;17)(q22;p13)	CDH11-USP6
	t(1;17)(p34.3;p13)	THRAP3-USP6
	t(3;17)(q21;p13)	CNBP-USP6
	t(9;17)(q22;p13)	OMD-USP6
	t(17;17)(q21;p13)	COL1A1-USP6
Angiofibroma	t(5;8)(p15;q13)	AHRR-NCOA2
Angiomatoid fibrous histiocytoma	t(12;22)(q13;q12)	EWSR1-ATF1
	t(2;22)(q33;q12)	EWSR1-CREB1
	t(12;16)(q13;p11)	FUS-ATF1
Alveolar rhabdomyosarcoma	t(2;13)(q35;q14)	PAX3-FKHR (PAX3-FOXO1)
Alveolar rhabdomyosarcoma	t(1;13)(p36;q14)	PAX7-FKHR (PAX7-FOXO1)
Alveolar soft-part sarcoma	der(17)t(X;17)(p11;q25)	ASPSCR1-TFE3
Chondroid lipoma	t(11;16)(q13;p13)	C11orf95-MKL2
Clear-cell sarcoma	t(12;22)(q13;q12)	EWSR1-ATF1
Clear-cell sarcoma	t(2;22)(q33;q12)	EWSR1-CREB1
Congenital/infantile fibrosarcoma	t(12;15)(p13;q25)	ETV6-NTRK3
Dermatofibrosarcoma protuberans/giant cell fibroblastoma	t(17;22)(q21;q13)	COLIA1-PDGFB
Desmoplastic small round-cell tumor	t(11;22)(p13;q12)	EWSR1-WT1
Endometrial stromal sarcoma	t(7;17)(p15;q11)	JAZF1-JJAZ1(SUZ12)
	t(6;7)(p21;p15)	JAZF1-PHF1
	t(6;10)(p21;p11)	EPC-PHF1
	t(10;17)(q22;p13)	YWHAE-FAM22A/B
	t(1;6)(p32~34;p21)	MEAF6-PHF1
Epithelioid hemangioendothelioma	t(1;3)(p36;q25)	WWTR1-CAMTA1
Epithelioid hemangioendothelioma	t(X;11)(p11.2;q22.1)	TFE3-YAP1
Ewing sarcoma; Primitive neuroectodemal tumor (PNET)	t(11;22)(q24;q12)	EWSR1-FLI1
	t(21;22)(q22;q12)	EWSR1-ERG
	t(7;22)(p22;q12)	EWSR1-ETV1
	t(2;22)(q33;q12)	EWSR1-FEV
	t(17;22)(q12;q12)	EWSR1-E1AF
	inv(22)(q21;q12)	EWSR1-ZSG
	t(16;21)(p11;q22)	FUS-ERG
Ewing-like bone sarcoma	inv(X)(p11.4p11.22)	BCOR-CCNB3
Ewing-like bone sarcoma	t(20;22)(q13;q12)	EWSR1-NFATC2
Extraskeletal myxoid chondrosarcoma	t(9;22)(q22;q12)	EWSR1-NR4A3
	t(9;17)(q22;q11)	TAF15-NR4A3
	t(9;15)(q22;q21)	TCF12-NR4A3
	t(3;9)(q11;q22)	TFG-NR4A3
Giant cell fibroblastoma	t(17;22)(q21;q13)	COL1A1-PDGFB
Inflammatory myofibroblastic tumor	t(1;2)(q22;p23)	TPM3-ALK
	t(2;19)(p23;p13)	TPM4-ALK
	t(2;17)(p23;q23)	CLTC-ALK
	t(2;2)(p23;q13)	RANBP2-ALK
	t(2;11)(p23;p15)	CARS-ALK
	inv(2)(p23;q35)	ATIC-ALK
	t(2;4)(p23;q21)	SEC31A-ALK
Lipoblastoma	t(7;8)(p22;q13)	COL1A2-PLAG1
Lipoma	t(3;12)(q27-28;q14-q15)	HMGA2-LPP
Lipoma	t(3;12)(q27-28;q14-q15)	LPP-HMGA2
Low-grade fibromyxoid sarcoma	t(7;16)(q33;p11)	FUS-CREB3L2
Low-grade fibromyxoid sarcoma	t(11;16)(p11;p11)	FUS-CREB3L1
Meningeal hemangiopericytoma	inv(12)(q13q13)	NAB2-STAT6
Mesenchymal chondrosarcoma	t(8;8)(q13;q21)	HEY1-NCOA2
Myoepithelial tumor of soft tissue and bone	t(6;22)(p21;q12)	EWSR1-POU5F1
	t(19;22)(q13;q12)	EWSR1-ZNF444
	t(1;22)(q23;q12)	EWSR1-PBX1
	t with 16p11	FUS
Myxoid/round-cell liposarcoma	t(12;16)(q13;p11)	FUS-DDIT3
Myxoid/round-cell liposarcoma	t(12;22)(q13;q12)	EWSR1-DDIT3
Nodular fasciitis	t(17;22)(p13;q13)	MYH9-USP6
Pericytoma	t(7;12)(p22;q13)	ACTB-GLI1
Pulmonary myxoid sarcoma	t(2;22)(q34;q12)	EWSR1-CREB1
Sclerosing epithelioid fibrosarcoma	t(7;16)(p22;q24)	FUS-CREB3L2
Sclerosing epithelioid fibrosarcoma	t(11;16)(p13;p11.2)	FUS-CREB3L1
Solitary fibrous tumor	inv(12)(q13q13)	NAB2-STAT6
Spindle cell rhabdomyosarcoma	t(6;8)(p21;q13)	SRF-NCOA2
Spindle cell rhabdomyosarcoma	t(8;11)(q13;p15)	TEAD-NCOA2
Synovial sarcoma	t(X;18)(p11;q11)	SS18-SSX1
		SS18-SSX2
		SS18-SSX4
Undifferentiated small round blue cell tumor	t(4;19)(q35;q13)	CIC-DUX4
Undifferentiated small round blue cell tumor	t(10;19)(q26;q13)	CIC-DUX4

Mojdeh Naghashpour, MD, PhD
Hematopathologist

Dr. Mojdeh Naghashpour joined NeoGenomics in 2018 as a hematopathologist. Throughout her medical career, Dr. Naghashpour has served in both academic and clinical centers throughout Florida, including Moffitt Cancer Center and University of South Florida in Tampa, Florida. Dr. Naghashpour received her medical degree from the University of Miami Miller School of Medicine. Her post-graduate education includes a PhD in Physics, a PhD in Physiology and Molecular Biology, and post-doctoral research at the University of Miami, in Miami, Florida. She received her residency training in anatomic and clinical pathology at the University of Pennsylvania, followed by fellowship training in hematopathology at Moffitt Cancer Center in Tampa, Florida, where she served as a hematopathologist and assistant professor at the University of South Florida. She is certified by the American Board of Pathology in anatomic and clinical pathology and hematopathology. As a life-long scientist, Dr. Naghashpour has authored a multitude of peer-reviewed articles, book chapter and scientific abstracts.

Galina I. Bannykh, MD
Staff Pathologist, Pharma Services

Dr. Galina I. Bannykh joined NeoGenomics as a Staff Pathologist for the Pharma Services division in 2018. Before joining NeoGenomics Laboratories, Dr. Bannykh served as a Staff Pathologist at Kaiser Permanente Medical Group, San Diego and prior to that she was a surgical pathologist and Associate Medical Director at Integrated Oncology (formerly U.S. Labs), LabCorp for over twelve years. Dr. Bannykh completed her post-graduate medical training in combined Anatomic and Clinical Pathology at the University of California, San Diego, where she served as Chief Resident and went on to complete her fellowship in Surgical Pathology with Dr. Noel Weidner. Subsequently, she completed her fellowship in Oncologic Pathology at Memorial Sloan-Kettering Cancer Center. Dr. Bannykh is board certified in Anatomic Pathology and Clinical Pathology. She has contributed to several publications.

Thomas K. Lee, MD, PhD
Surgical Pathologist

Dr. Thomas K. Lee joined NeoGenomics as a Surgical Pathologist in 2018. Dr. Lee previously served as an Associate Clinical Professor of Pathology and Urology at University of California, Irvine, where his roles included Program Director of the Pathology Residency Program and Director of the Surgical Pathology Fellowship Program, and as a Pathologist and Partner at CellNetix Pathology and Swedish Medical Center. Dr. Lee completed his Fellowship in Surgical Pathology at Stanford University Medical Center, and Residency/Fellowship in Anatomic and Urologic Pathology at the John Hopkins Medical Institutions. He received his PhD in Toxicology and MS in Environmental Studies from the University of Rochester. Dr. Lee has been the recipient of several awards, including the Top Doctor List from Seattle Metropolitan Magazine. In addition to teaching at University of California, Irvine, Dr. Lee has presented at national and international meetings, and actively publishes. Dr. Lee’s areas of diagnostic expertise include urologic, gastrointestinal, breast, and gynecological pathology, with a strong interest in soft tissue pathology as well.

Maher Albitar, MD
Chief Medical Officer and Director of Research and Development

Dr. Albitar, M.D., is formally trained in clinical pathology, hematopathology, and genetics. During his professional and academic tenure, he has published over 300 publications including peer-reviewed papers, review articles and book chapters focused on molecular characterization and diagnosis of cancer. He has served as Chief Medical Officer and Director of Research and Development at NeoGenomics since 2012. Prior to NeoGenomics, Dr. Albitar served as the Medical Director of Hematopathology and Oncology and Chief of R&D for Hematopathology and Oncology, Quest Diagnostics. He has held academic positions at The University of Texas MD Anderson Cancer Center as Tenured Full Professor, Director of Leukemia and Director of Molecular Laboratory in the Departments of Laboratory Medicine/Pathology.

Adrian M. Padurean, MD, MBA
Medical Director (Fort Myers, Florida) and Hematopathologist

Dr. Padurean joined NeoGenomics as the Medical Director of the Fort Myers, Florida laboratory in 2016. Prior to joining NeoGenomics, Dr. Padurean served as a Hematopathologist at AmeriPath Milwaukee. Dr. Padurean received his medical degree from Institutul de Medicina in Timisoara, Romania. He conducted medical research in the field of cardiovascular biology at Massachusetts General Hospital/Harvard Medical School and Mount Sinai Medical Center, New York. Subsequently, he completed his pathology residency at Regions Hospital in St. Paul, Minnesota and hematopathology fellowship training at the University of Minnesota. Dr. Padurean has served with distinction in numerous positions of importance in the clinical and academic service arenas, including Assistant Professor at University of Minnesota Medical School in Minneapolis, Minnesota; Staff Pathologist at VA Medical Center in Minneapolis, Minnesota; and Staff Pathologist/Hematopathologist and Director of Hematology Laboratories of Wheaton Franciscan Healthcare in Milwaukee, Wisconsin. Dr. Padurean is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology by the American Board of Pathology. He earned an MBA in Healthcare Administration from the Quinlan School of Business at Loyola University Chicago.

Neal S. Goldstein, MD
Senior Pathologist

Dr. Goldstein completed his residency at UCLA and surgical pathology fellowship at Barnes Hospital/Washington University. He was a staff anatomic pathologist and director of immunohistochemistry laboratory at William Beaumont Hospital in Royal Oak, MI for 14 years and director of the anatomic molecular laboratory for seven years. He has published 130 peer-reviewed articles and five book chapters. He has taught numerous courses at the ASCP, USCAP, and CAP and served on numerous consensus conferences over his 21 years of practice. He was part of the Gynecology Oncology Group Pathology committee for 10 years and USCAP education committee for four years. He has given talks throughout the United States at many state and city pathology societies and throughout the world. Dr. Goldstein’s primary diagnostic interests lie in the areas of breast, gastrointestinal, gynecologic, liver, and molecular pathology and immunohistochemistry.

Lawrence M. Weiss, MD
Medical Director (Aliso Viejo, California) and Director of Pathology Services

Dr. Weiss received his BS summa cum laude and M.D. summa cum laude from the University of Maryland. He completed a residency in Anatomic Pathology at the Brigham and Women’s Hospital and a fellowship in surgical pathology at Stanford University Medical Center. He was previously an Assistant Professor of Pathology at Stanford, President of the Medical Staff, and Chairman of Pathology at the City of Hope. He is the author of over 500 papers and book chapters, as well as over a dozen books, including an AFIP Lymph Node Fascicle, Applied Immunohistochemistry, Lymph Nodes, and Knowles’ Hematopathology. His laboratory discovered the first molecular evidence linking the Epstein-Barr virus with Hodgkin Lymphoma. He has won numerous awards, including the Benjamin Castleman, Arthur Purdy Stout, and the United States-Canadian Academy of Pathology Young Investigator Award, and has delivered more than 250 national and international talks in pathology, including several named lectureships. He is on the editorial board of ten scientific journals, and is a past President of the Los Angeles Society of Pathologists. He has been listed in the book The Best Doctors in America since 1994. Dr. Weiss’s diagnostic interests lie in lymph node pathology, adrenal pathology, solid tumor pathology, and immunohistochemistry.

Lawrence M. Weiss, MD
Medical Director (Aliso Viejo, California) and Director of Pathology Services

Stephanie Bywater
Chief Compliance Officer

Stephanie has over 13 years’ experience developing and overseeing programs to ensure compliance with various global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining the Company, Stephanie managed global compliance operations for and was the Compliance Officer for the Americas Region at Varian Medical Systems Inc. from 2015 to 2017, with a focus on global anti-corruption and ethical compliance requirements. Prior to Varian, she was the Compliance and Privacy Officer for Myriad Genetic Laboratories, where she implemented and provided oversight for programs supporting compliance with the Anti-kickback Statute, Stark Law, the Food and Drug Administration, billing and reimbursement, research, and global data privacy and protection requirements from 2010 to 2015. Stephanie also has a wealth of compliance experience in large health systems, behavioral health, and has served as an internal auditor. She has a Bachelor of Science in Healthcare Administration from Northern Illinois University and is a Certified Healthcare Professional (CHP), Certified in Healthcare Privacy (CHP), and a Certified Internal Auditor (CIA).

Kathryn McKenzie
Vice President – Finance, Principal Accounting Officer

Ms. McKenzie has served as NeoGenomics Principal Accounting Officer and Vice President of Finance since October 2017. Prior to joining the Company, Ms. McKenzie held various roles at Chico’s FAS, Inc. during the period from 2012 to 2017. These roles included Assistant Controller and Director of Financial Reporting and Treasury. Ms. McKenzie also previously served as Audit Manager for Ernst and Young from 2007 to 2012. Ms. McKenzie is a Certified Public Accountant and holds a Master’s of Science in Accountancy from the University of North Carolina Wilmington.

Bill Bonello
Chief Strategy and Corporate Development Officer

Bill Bonello is the Vice President, Strategy, Corporate Development and Investor Relations for NeoGenomics, Inc. Prior to joining NeoGenomics, Bill spent nearly twenty years as a healthcare equity analyst covering diagnostic services and product stocks for Piper Jaffray, Wachovia Securities, RBC, and Craig-Hallum Capital Group. Bill was also the Senior Vice President for Investor Relations at LabCorp. Bill earned a BA from Carleton College and an MBA from the Kellogg School of Management at Northwestern University.

Shehla Arain, MD
Surgical Pathologist, Pharma Services

Dr. Arain joined NeoGenomics in 2016. Dr. Arain is a board-certified pathologist with sub-specialty fellowship training in gastrointestinal pathology and cytopathology. Her professional experience includes roles as Medical Laboratory Director and staff pathologist at Specialized Pathology Laboratories, Centennial Pathologists and Heartland Clinic. Dr. Arain completed training as a Cytopathology Fellow at the University of California, Irvine and as a GI/Liver Pathology Fellow at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Arain has spoken at several conferences and has been involved in several case presentations, research projects and publications.

NGS Ewing Sarcoma Fusion Profile

The NGS Ewing Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations relevant in Ewing's sarcoma in the gene EWSR1, plus its fusion partners.

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.

Printable Test Details

Tumor Type	Translocation	Fusion Partners
Clear-cell sarcoma	t(12;22)(q13;q12)	EWSR1-ATF1
Clear-cell sarcoma	t(2;22)(q33;q12)	EWSR1-CREB1
Desmoplastic small round-cell tumor	t(11;22)(p13;q12)	EWSR1-WT1
Ewing sarcoma; Primitive neuroectodemal tumor (PNET)	t(11;22)(q24;q12)	EWSR1-FLI1
	t(21;22)(q22;q12)	EWSR1-ERG
	t(7;22)(p22;q12)	EWSR1-ETV1
	t(2;22)(q33;q12)	EWSR1-FEV
	t(17;22)(q12;q12)	EWSR1-E1AF
	inv(22)(q21;12)	EWSR1-ZSG
Ewing-like bone sarcoma	t(20;22)(q13;q12)	EWSR1-NFATC2
Myoepithelial tumor of soft tissue and bone	t(6;22)(p21;q12)	EWSR1-POU5F1
	t(19;22)(q13;q12)	EWSR1-ZNF444
	t(1;22)(q23;q12)	EWSR1-PBX1
Extraskeletal myxoid chondrosarcoma	t(9;22)(q22;q12)	EWSR1-NR4A3
Myxoid/round-cell liposarcoma	t(12;22)(q13;q12)	EWSR1-DD1T3
Pulmonary myxoid sarcoma	t(2;22)(q34;q12)	EWSR1-CREB1
Angiomatoid fibrous histiocytoma	t(12;22)(q13;q12)	EWSR1-ATF1
Angiomatoid fibrous histiocytoma	t(2;22)(q33;q12)	EWSR1-CREB1

NGS Pediatric Sarcoma Fusion Profile

The NGS Pediatric Sarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations related to pediatric sarcomas in the genes ALK, EWSR1, FUS, FLI1, NTRK3, USP6, plus their fusion partners.

Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.

Printable Test Details

Tumor Type	Translocation	Fusion Partners
Angiomatoid fibrous histiocytoma	t(12;22)(q13;q12)	EWSR1-ATF1
	t(2;22)(q33;q12)	EWSR1-CREB1
	t(12;16)(q13;p11)	FUS-ATF1
Congenital/infantile fibrosarcoma	t(12;15)(p13;q25)	ETV6-NTRK3
Inflammatory myofibroblastic tumor	t(1;2)(q22;p23)	TPM3-ALK
	t(2;19)(p23;p13)	TPM4-ALK
	t(2;17)(p23;q23)	CLTC-ALK
	t(2;2)(p23;q13)	RANBP2-ALK
	t(2;11)(p23;p15)	CARS-ALK
	inv(2)(p23;q35)	ATIC-ALK
	t(2;4)(p23;q21)	SEC31A-ALK
Nodular fasciitis	t(17;22)(p13;q13)	MYH9-USP6
Pericytoma	t(7;12)(p22;q13)	ACTB-GLI1

Antony Bakke, PhD, D(ABMLI)
Consultant, Flow Cytometry

Dr. Bakke received his Ph.D. in biochemistry from Caltech in Pasadena, CA. During a postdoctoral fellowship at the Scripps Clinic and Research Foundation in San Diego, CA he learned flow cytometry on an early BD FACS II. He joined the Rheumatology faculty at the University of Southern California in 1980 and completed research projects on SLE, scleroderma, leprosy and natural killer cells, while directing flow cytometry labs for both the Department of Medicine and the Cancer Center. In 1984, he joined the pathology faculty at Oregon Health & Science University Hospital in Portland, OR. During 27 years at OHSU, Dr. Bakke established both the Clinical Immunology/Flow Cytometry Laboratory in the Pathology Department and the Knight Cancer Institute Core Flow Cytometry Resource. He became a full professor at OHSU and completed research projects involving leukemia, lymphoma, PNH, immune thrombocytopenic purpura, rheumatoid arthritis, bacterial and viral infection. Dr. Bakke became a Diplomate of the American Board of Medical Laboratory Immunology in 2004 and served on the council for the International Clinical Cytometry Society from 2005 to 2010. Dr. Bakke was an early adopter of eight and ten-color flow cytometry and cell sorting for clinical specimens.

Steven G. Brodie, PhD, FACMG
Vice President, Worldwide Pharma Services Operations

Dr. Brodie is the Vice President of Worldwide Pharma Services Operations at NeoGenomics Laboratories. He is also the Laboratory Director for NeoGenomics Europe S.A. Previously he served as the company’s President of the Pharma Services division, Chief Scientific Officer, Director of BioPharma Operations, Laboratory Director, and Director of Molecular and Cytogenetics. Prior to joining NeoGenomics in 2011, Dr. Brodie served as Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Specialty Laboratories/Quest Diagnostics in Valencia, CA. Dr. Brodie trained pathology residents in genetic testing at both Loma Linda University Medical Center, where he served as the Affiliate Rotation Director, and University of Southern California, Keck School of Medicine, where he served as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and UCLA David Geffen School of Medicine. Dr. Brodie received his genetics training at the UCLA/Cedar-Sinai Medical Center medical genetics training program in Los Angeles, CA. He received his Ph.D. from UNM School of Medicine and completed Clinical Genetics training in Cytogenetics and Molecular Genetics at UCLA. Dr. Brodie is Board Certified by the American Board of Medical Genetics in these specialties and holds Director licenses in Florida, California, and New York. Throughout his career, Dr. Brodie has held various research and clinical positions at the NIH, UNM and UCLA, and comes to us after directing high throughput testing in Cytogenetics, FISH, Molecular Genetics, and Oncology for Quest Diagnostics, Nichols Institute. He is also a CAP approved inspector.

Lawrence M. Weiss, MD
Medical Director (Aliso Viejo, California) and Director of Pathology Services

Josette William Ragheb, MD, PhD
Medical Director, Pharma Services and Hematopathologist

Dr. William joined NeoGenomics as Medical Director, Pharma Services and Hematopathologist in 2017. She previously served as a general pathologist for multiple laboratories and hospitals, including Quest Diagnostics Nichols Institute and Natividad Medical Center. In addition, Dr. William worked as a Hematopathology Consultant for DAKO/Agilent, and has extensive experience in clinical trials as a researcher for Northwestern University Feinberg School of Medicine. She completed her Hematopathology Fellowship and Anatomic and Clinical Pathology Residency at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. William obtained her medical degree from Ain Shams University and her PhD in Clinical Pathology, Immunology from Cairo University. In addition, Dr. William has spoken nationally and internationally, and has contributed toward several publications.

Adrian M. Padurean, MD, MBA
Medical Director (Fort Myers, Florida) and Hematopathologist

J. Christopher Mixon, MD
Medical Director (Nashville, Tennessee)

Dr. Mixon is the Medical Director for the NeoGenomics Tennessee laboratory, and serves as the Medical Director of LabPlus within St. Thomas Health System and of the medical laboratories at St. Thomas Midtown and St. Thomas West hospitals in Nashville, TN. Dr. Mixon received his medical degree from the University of South Alabama, College of Medicine in Mobile, Alabama, where he developed his interest and skill in cytogenetics. He received his pathology residency training at Vanderbilt University Medical Center. He has been active in cytogenetics throughout his entire medical career, and has a special interest in cancer cytogenetics. He is board certified in Anatomic and Clinical Pathology by the American Board of Pathology.

Sally S. Agersborg, MD, PhD
Director of Hematopathology Services

Dr. Agersborg joined NeoGenomics as a Hematopathologist in 2011. Prior to joining NeoGenomics, Dr. Agersborg worked as a Hematopathologist at Quest Diagnostics Nichols Institute. She completed her post-graduate medical training in Anatomic Pathology at the University of California, San Francisco, including fellowships in Surgical Pathology and Hematopathology. Beginning her educational career at Stanford University, Dr. Agersborg completed a co-terminal B.S. with Honors and M.S. in Biology. After graduating from Stanford University, Dr. Agersborg studied at the University of Virginia, where she earned a combined M.D. in Medicine and Ph.D. in Microbiology. Dr. Agersborg has written many publications, including peer reviewed and non-peer reviewed books, chapters, articles, and a multitude of abstracts.

Sharon Virag
Chief Financial Officer

Sharon Virag joined NeoGenomics in 2018 as Chief Financial Officer. Sharon is responsible for all finance functions and related activities. She is also a member of the Financial Accounting Standards Advisory Council (FASAC), a group that advises the Financial Accounting Standards Board (FASB) on matters related to board projects and agenda prioritization.

Prior to NeoGenomics, Sharon served as Head of Corporate Finance and Chief Accounting Officer of AETNA, where she was responsible for controllership, tax, treasury, Finance Transformation and Finance Shared Services for the company from 2015 to 2017. Prior to Aetna, between 2008 and 2015, Sharon held various positions in Controllership including Chief Accounting Officer of AES Corp., Global Controller positions at several General Electric businesses and Assistant Corporate Controller at General Motors. Included in these roles were two overseas assignments, living with her family in both Shanghai, China and Florence, Italy.

In addition to her private sector experience, Sharon was with the Public Company Accounting Oversight Board (“PCAOB”) from 2005 to 2008, where she served as the project leader for Auditing Standard No. 5, the Board’s requirements/regulations for Sarbanes-Oxley Section 404.

Robert J. Shovlin
President, Clinical Services Division

Mr. Shovlin joined NeoGenomics in 2014 as the Chief Operating Officer, and now serves as the President, Clinical Services Division. Previously, he served as Chief Development Officer for Bostwick Laboratories, a leading provider of anatomic pathology testing services. From 2005 to 2011, he served in several positions of increasing responsibility, ultimately as President and Chief Executive Officer for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director of Anatomic Pathology and as Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer, in the United States Marine Corps from 1992 until 1997 where he served as a Platoon Commander and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at The Basic School. He received his bachelor’s degree from Pennsylvania State University, and his MBA in Finance from Rutgers University.

Steve A. Ross
General Counsel

Mr. Ross has served as Chief Information Officer of NeoGenomics since 2013. Mr. Ross brings over 25 years of technology leadership experience while most recently serving as the Vice President of Technology for Chico’s FAS, Inc., from 2003 to 2013. Chico’s is a multi-branded retailer, with more than 1,550 stores, an award winning eCommerce and Direct-to-Consumer offering, and $2.6 billion in annual revenue. In addition to retail, Mr. Ross has extensive technology experience in the manufacturing, engineering, and financial sectors, having served in a variety of management and consulting roles with Motorola, DirecTV, American Express, and Target. Mr. Ross received his bachelor’s degree from New Mexico State University.

Denise E. Pedulla
General Counsel

Ms. Pedulla joined NeoGenomics in 2015 as the company’s General Counsel. From 2011 to 2015, Ms. Pedulla served as a Principal at Berkeley Research Group in its Compliance and Regulatory Risk Management services division and was engaged in private law practice. Prior to that, from 2008 to 2011, Ms. Pedulla was the Senior Vice President and Chief Compliance Officer at Orthofix International NV, a global orthopedic medical device company. From 2000 to 2008, Ms. Pedulla, a health care lawyer, was engaged in private law practice and provided legal counsel to hospitals, clinical laboratories, durable medical equipment suppliers and other health care providers in the areas of fraud and abuse, coverage, billing and reimbursement, regulatory compliance, corporate governance, contracting, and government affairs. From 1996 to 2000, Ms. Pedulla was employed at Fresenius Medical Care North America in positions of increasing responsibility, including Associate General Counsel and Vice President of Compliance, Regulatory and Government Affairs for the company’s clinical laboratory division. Ms. Pedulla received a B.S. in Nursing and Psychology from Boston College, a J.D. from Suffolk Law School, and an M.P.H. in Health Policy and Management from Harvard University. She also holds a Certification in Health Care Compliance (CHC) from the Health Care Compliance Association. Ms. Pedulla is a licensed attorney in Massachusetts and Florida and is a member of the American Health Lawyers Association and the Health Law Sections of the American, Florida, and Massachusetts Bar Associations.

Steven C. Jones
Executive Vice President

Mr. Jones has served as a director of NeoGenomics since 2003, as Executive Vice President of Finance since 2009, and as Chief Compliance Officer since 2013. Mr. Jones served as Chief Financial Officer of the Company from 2003 until 2009. He is a Managing Director in Medical Venture Partners, LLC, a venture capital firm established in 2003 for the purpose of making investments in the healthcare industry. Mr. Jones is also the founder and Chairman of the Aspen Capital Group and has been President and Managing Director of Aspen Capital Advisors since 2001. Prior to that, Mr. Jones was a chief financial officer at various public and private companies and was a Vice President in the Investment Banking Group at Merrill Lynch & Co., Inc. Mr. Jones received his bachelor's degree in Computer Engineering from the University of Michigan in 1985 and his MBA from the Wharton School of the University of Pennsylvania in 1991. He also serves as Chairman of the Board of T3 Communications, Inc. and serves on the Board of Directors of XG Sciences, Inc.

George A. Cardoza
President, Pharma Services

Mr. Cardoza was appointed as the President of Pharma Services in March 2018. He has been with NeoGenomics since November 2009, serving as the Company’s Chief Financial Officer. Prior to that he was the Chief Financial Officer at Protocol Integrated Direct Marketing. Mr. Cardoza spent fifteen years with Quest Diagnostics, including years when it was still part of Corning Inc. With Corning Inc. he worked with the Corning Life Sciences Division, which did several acquisitions in the Pharma services space. These acquisitions formed the pieces of Covance, which Corning spun out at the same time as Quest in 1996. Mr. Cardoza has worked closely with NeoGenomics Pharmaceutical Services and Clinical Trials division, which was combined into the Clinical Trials arm of Clarient Inc. when it was acquired from General Electric Healthcare in December 2015.

Steven G. Brodie, PhD, FACMG
Vice President of Worldwide Pharma Services Operations

Jennifer Balliet
Chief Culture Officer

Mrs. Balliet joined NeoGenomics in 2008 as Director, Human Resources. Since then, she has been appointed as Vice President, Human Resources in 2015 and Chief Culture Officer in 2016. Mrs. Balliet has managed Human Resources as the Company grew from 100 employees to more than 900 employees. She is responsible for all areas of Human Resources, including recruiting, training, compensation, incentive plans, and organizational development. Mrs. Balliet received her Bachelor of Science degree in Psychology and her Master of Science degree in Business Management from the University of Florida.

Maher Albitar, MD
Chief Medical Officer and Director of Research and Development

Renuka Agrawal, MD
Hematopathologist

Dr. Agrawal is board certified in Anatomic and Clinical Pathology as well as in Hematopathology. She completed her residency in the Combined Anatomic and Clinical Pathology program at Loma Linda University Medical Center after which she went on to complete a Hematopathology Fellowship at the City of Hope National Medical Center with Dr. Lawrence Weiss. She specializes in flow cytometry, review of bone marrows, lymph nodes and other hematopathology consults, as well as fluorescence in-situ hybridization.

Saskia Boisot, MD
Hematopathologist

Dr. Boisot is a practicing pathologist, and is affiliated with several hospitals in the San Diego area. Dr. Boisot received her medical degree and completed her residency in Anatomic and Clinical Pathology from the University of California, San Diego School of Medicine. She completed her transitional internship at Loma Linda University. Dr. Boisot completed her fellowship in hematopathology at Scripps Clinic – Scripps Green Hospital. Dr. Boisot is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology.

Wayne W. Chen, MD, PhD
Director of Lymphoma Services and Hematopathologist

Dr. Chen is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. Dr. Chen received his medical degree from Nanjing Medical University, his master’s degree from Peking University Health Science Center, and his Ph.D. from National Institute for Viral Disease Control and Prevention, China CDC. He was a postdoctoral fellow and then senior research associate at The Scripps Research Institute in La Jolla, CA. Dr. Chen completed his residency in Anatomic and Clinical Pathology at University of Arizona, Tucson, and completed his two-year fellowship in Hematopathology with subspecialties in lymphoma and lymph node pathology at NCI, NIH in Bethesda, MD, under Dr. Elaine S. Jaffe. Before joining NeoGenomics Laboratories as Director of Lymphoma Services in 2013, Dr. Chen was a hematopathologist and Associate Medical Director at Integrated Oncology (formerly U.S. Labs), LabCorp for over seven years.

Takako Mitsuhashi, MD, PhD
Dermatopathologist and Surgical Pathologist

Dr. Mitsuhashi is board certified in Anatomic Pathology, Clinical Pathology, and Dermatopathology. Dr. Mitsuhashi received her medical degree from Tokyo Women’s Medical College in Japan, and her Ph.D. from Gunma University, School of Medicine in Maebashi, Japan. She was a post-doctoral fellow at Cardiovascular Research Institute in University of California, San Francisco. Dr. Mitsuhashi completed her residency in University of California, Irvine, and completed her fellowship in Dermatopathology at University of California, Irvine, under Dr. Ronald Barr. She was a clinical instructor in Department of Pathology, University of California Irvine, during 2003 to 2004. Prior to joining NeoGenomics, Dr. Mitsuhashi served as the Associate Medical Director at Integrated Oncology (formerly U.S. Labs) for 11 years.

Paul Kirshman, MD
Staff Pathologist

Dr. Kirshman currently serves as a Staff Pathologist at NeoGenomics, and served as a Staff Pathologist at Clarient Diagnostic Services, Inc. for six years prior to the NeoGenomics acquisition in 2015. Previously, Dr. Kirshman served as a Staff Pathologist at Urocor and US Labs, where his focus was on prostate pathology. Dr. Kirshman received his medical degree from the University of Montpellier, France; residency training at Westchester County Medical Center in Valhalla, NY; and fellowship training in molecular pathology under Dr. Mark Sobel at National Institutes of Health in Bethesda, MD.

Neal S. Goldstein, MD
Senior Pathologist

Guohua (Joshua) Zhao, MD, PhD.
Hematopathologist

Dr. Zhao is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology, with over 29 years of professional experience. Dr. Zhao previously served as a staff pathologist at Cottage Hospital, Santa Barbara, CA and as a clinical instructor in the Department of Pathology, University of California, Irvine.

Fan Yang, MD, PhD
Hematopathologist

Dr. Yang shares more than 25 years of experience in medical research and clinical service with subspecialties in Hematology, Anatomic Pathology and Clinical Pathology. Formerly an Assistant Professor of Pathology at the Medical College of Wisconsin and University of Florida, Dr. Yang received his resident training at Albany Medical Center in New York and a Fellowship of Hematopathology from the City of Hope National Medical Center in Duarte, California.

Jian-Feng Wang, MD, PhD
Hematopathologist

Dr. Wang is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. Dr. Wang completed his fellowship training in Hematopathology at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA and his residency training at Berkshire Medical Center/University Massachusetts Medical School in Pittsfield, MA. Before his residency training, he served as junior faculty at Harvard Medical School and as an assistant research scientist at Beth Israel Deaconess Medical Center in Boston, MA. He has more than 50 publications and presentations in scientific journals and at national/international scientific meetings, and his research focus is hematopoiesis and endothelial cell biology.

Jesalyn J. Taylor, MD
Hematopathologist

Dr. Taylor brings her talent to NeoGenomics after several years as a hematopathologist at a private laboratory in California. Dr. Taylor has a specific interest in quality control and quality assurance. Dr. Taylor completed her pathology resident training at University of South Alabama Medical Center, and her hematopathology fellowship at The Methodist Hospital in Houston, TX.

Dennis P. O’Malley, MD
Hematopathologist

Shi-Ping Jiang, MD, PhD
Hematopathologist and Surgical Pathologist

Dr. Jiang is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology. She specialized in Hematology and Oncology in China and Germany. Dr. Jiang completed her residency in pathology at the University of Oklahoma Health Sciences Center and the George Washington University Medical Center. She also completed a fellowship in hematopathology at Scripps Clinic in La Jolla, California. Dr. Jiang has extensive experience in hematopathology and vital skills in surgical pathology and served as the medical director at Tustin Center of Integrated Oncology/Labcorp, Inc.

Armin G. Jegalian, MD, PhD.
Hematopathologist

Prior to joining NeoGenomics, Dr. Jegalian was a staff physician at the Cleveland Clinic, where she was responsible for a high volume of diverse hematopathology cases and teaching trainees. She worked closely with world-renowned lymphoma pathologist Dr. Elaine S. Jaffe during a hematopathology fellowship at the National Institutes of Health. Dr. Jegalian completed her undergraduate degree, medical degree, and Ph.D. in Molecular Biology (Medical Scientist Training Program), and her four-year pathology residency at University of California, Los Angeles. She is board certified in Anatomic Pathology, Clinical Pathology, and Hematopathology, and has written several well-cited publications.

Kim Janatpour, MD, MA
Hematopathologist

Dr. Janatpour brings more than 20 years of pathology experience to NeoGenomics, most recently in a private laboratory where she was Director of Medical Affairs and Director of Pathologist Research. Dr. Janatpour completed her pathology resident training and Hematopathology fellowship at University of California, Davis Medical Center. She also holds a master’s degree in Clinical Research and she has an extensive background in hematopathology research.

Jennifer Hummel, MD, MPH
Hematopathologist / Molecular Pathologist

Dr. Hummel joined NeoGenomics as a Hematopathologist / Molecular Pathologist in 2016. Previously, Dr. Hummel served as a Hematopathologist / Molecular Pathologist for Novartis/Genoptix from 2014 to 2016 and Clarient Diagnostic Services from 2012 to 2014. Dr. Hummel completed her Molecular and Genetic Pathology fellowship at University of Pittsburgh Medical Center under Dr. Jeffrey Kant and her Hematopathology fellowship and Pathology residency at University of Michigan. Dr. Hummel obtained her medical degree from Medical College of Wisconsin, her Masters of Public Health in Infectious Diseases and Immunity from University of California, Berkeley and her Bachelors of Science from University of Wisconsin, Madison. Dr. Hummel has contributed to several publications and abstracts in hematopathology and solid tumors. In addition, Dr. Hummel has served as a Certified Inspector for the College of American Pathologists (CAP).

Anselm Hii, MD, FCAP
Senior Pathologist and Director, Consultative Services

Dr. Hii is a practicing pathologist and board certified in Anatomic and Clinical Pathology as well as Hematology. Prior to joining NeoGenomics, he served as Senior Pathologist and Director, Consultative Services at Clarient Pathology Services and Assistant Medical Director at U.S. Labs in Irvine, CA. He received his medical degree as well as residency training at Loma Linda University and went on to complete a surgical pathology fellowship at the Los Angeles County-University of Southern California Medical Center and a fellowship in hematopathology at Cedars-Sinai Medical Center in Los Angeles. Dr. Hii is the current California Tumor Tissue Registry Co-Director for Web and Multimedia Development. He is a member of the College of American Pathologists, American Society for Clinical Pathology, and American Society of Hematology.

Vladislav Chizhevsky, MD, FCAP, FASCP
Senior Hematopathologist and Medical Director, Flow Cytometry

Dr. Chizhevsky completed his residency in the Combined Anatomic and Clinical Pathology program at Saint Barnabas Medical Center in New Jersey where he served as Chief Resident. Dr. Chizhevsky went on to complete a fellowship in Hematopathology at City of Hope National Medical Center with Dr. Lawrence Weiss. He has authored many publications in peer-reviewed medical journals. Dr. Chizhevsky’s diagnostic interests lie in flow cytometry, lymph node pathology, adult and pediatric bone marrow pathology, immunohistochemistry, immunotherapy and molecular diagnostics of both solid tumors and hematolymphoid neoplasms. He is a member of the College of American Pathologists, American Society for Clinical Pathology and International Clinical Cytometry Society. Dr. Chizhevsky holds certifications in HER2 DUAL ISH Interpretation, PD-L1 (SP142; Atezolizumab) Urothelial Carcinoma Interpretation, PD-L1 (22C3; Keytruda^®) NSCLC Interpretation, PD-L1 (28.8; Opdivo^®) NSCLC Interpretation, and PD-L1 (28.8; Opdivo^®) Melanoma Interpretation, as well as a Black Belt in Six Sigma.

Douglas M. VanOort
Chairman of the Board of Directors and Chief Executive Officer

Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a private equity firm, and a Founding Managing Partner of a venture capital firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated and at its spin-off company, Quest Diagnostics, Inc. During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Inc. which was then a $1.5 billion newly formed NYSE-traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc., including Executive Vice President. Corning Life Sciences Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning Incorporated, including Director of Mergers & Acquisitions. Mr. VanOort currently serves as a member of the Board of Directors of several privately-held companies, and is a principal owner of a privately-held retail hardware store chain. Mr. VanOort is a graduate of Bentley University.

Test Menu